Short‐ and long‐acting synthetic pentasaccharides

Koopman MMW, Büller HR (Academic Medical Centre, Amsterdam, The Netherlands). Short‐ and long‐acting synthetic pentasaccharides (Minisymposium). J Intern Med 2003; 254: 335–342. Inhibition of activated coagulation factor X (FXa) is an attractive target for antithrombotic treatment strategies, becaus...

Full description

Saved in:
Bibliographic Details
Published in:Journal of internal medicine 2003-10, Vol.254 (4), p.335-342
Main Authors: Koopman, M. M. W., Büller, H. R.
Format: Article
Language:English
Subjects:
Acute Disease
anticoagulant
Anticoagulants - therapeutic use
Blood Coagulation - drug effects
Coronary Disease - prevention & control
factor Xa inhibitor
Factor Xa Inhibitors
Fibrinolytic Agents - therapeutic use
Fondaparinux
Hemorrhage - drug therapy
Humans
Oligosaccharides - therapeutic use
pentasaccharide
Polysaccharides - therapeutic use
Thromboembolism - drug therapy
Thromboembolism - prevention & control
Thrombosis - drug therapy
Thrombosis - prevention & control
Venous Thrombosis - prevention & control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Koopman MMW, Büller HR (Academic Medical Centre, Amsterdam, The Netherlands). Short‐ and long‐acting synthetic pentasaccharides (Minisymposium). J Intern Med 2003; 254: 335–342. Inhibition of activated coagulation factor X (FXa) is an attractive target for antithrombotic treatment strategies, because of the central position of FXa in the coagulation cascade. Most of the now available anticoagulant drugs have inhibitory effects not only on FXa, but also on thrombin. With the development of pentasaccharides, a new class of antithrombotic agents has emerged that acts by specific inhibition of FXa and lacks activity against FIIa. Fondaparinux, the first synthetic short‐acting pentasaccharide, has been evaluated, in a large phase II and III clinical programme concerning prophylaxis and treatment of venous thromboembolism and also in phase II studies in patients with acute coronary syndromes. Idraparinux, the long‐acting pentasaccharide, has been studied in a dose‐finding study in patients with established deep‐vein thrombosis and phase III studies are now planned in patients with venous thromboembolism and in patients with atrial fibrillation.
ISSN:0954-6820
1365-2796
DOI:10.1046/j.1365-2796.2003.01226.x